Zinc Sulfate Unspecified Form

證據等級: L5

預測適應症: 5 個

Zinc Sulfate: From Trace-Element Supplementation to Multiple Predicted Indications

One-Sentence Summary

This evidence pack does not contain documented original-indication or regulatory data for zinc sulfate (unspecified form) — it is not currently marketed in Taiwan or reflected with any Taiwan NDA. TxGNN has generated 5 predicted new indications for this candidate, but the strength of supporting evidence varies enormously: only dermatitis (zinc-deficiency / radiation-induced subtypes) reaches RCT-level evidence (L2), one indication (bronchitis) has mixed/indirect literature (L3), and the remaining three (severe nonproliferative diabetic retinopathy, diabetic retinopathy, diabetic cataract) are supported by mechanistic reasoning alone (L5), with little to no zinc-sulfate-specific literature.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (`original_indications` is empty; zinc sulfate is generally known as a trace-element/mineral supplement)
Number of Predicted Indications Evaluated	5
Best-Supported Indication	Dermatitis (zinc-deficiency and radiation-induced subtypes) — TxGNN score 99.15%, Evidence Level L2
US/Taiwan Market Status	Not marketed (0 licenses)
Number of NDAs	0
Overall Recommended Decision	Proceed with Guardrails (dermatitis subtypes only) / Hold for all other predicted indications

Summary of All Predicted Indications

Rank	Predicted Indication	TxGNN Score	Evidence Level	Decision Stage	Recommendation
1	Severe nonproliferative diabetic retinopathy	99.84%	L5	S0	Hold
2	Diabetic retinopathy	99.76%	L5	S0	Hold
3	Bronchitis	99.61%	L3	S1	Research Question
4	Diabetic cataract	99.35%	L5	S0	Hold
5	Dermatitis	99.15%	L2	S2	Proceed with Guardrails

Note: TxGNN prediction score does not correlate with evidence strength here — the highest-ranked prediction (severe NPDR) has zero supporting literature, while the lowest-ranked (dermatitis) has the strongest clinical evidence.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this candidate (original_moa: [Data Gap], flagged as a High-severity data gap, DG002). Based on general pharmacological knowledge, zinc is an essential trace element and cofactor for Cu/Zn-superoxide dismutase (SOD), metallothionein, and numerous enzymes involved in immune regulation, epithelial differentiation, and antioxidant defense. This general mechanistic role underlies all five TxGNN predictions, but the strength of the underlying rationale differs sharply by indication:

Dermatitis (strongest candidate): Zinc deficiency is a well-established, direct cause of a specific dermatitis subtype (acrodermatitis enteropathica), for which zinc replacement is the accepted standard of care — this is fundamentally a deficiency-correction indication rather than a novel repurposing mechanism. Separately, zinc’s anti-inflammatory and keratinocyte-modulating properties have RCT support for prevention of radiation-induced dermatitis. However, many of the retrieved literature results concern veterinary/agricultural dermatitis (cattle, sheep, poultry) and are not applicable to human general dermatitis (eczema, contact dermatitis) — species and subtype mismatches should be excluded during evidence curation.

Bronchitis: Zinc’s immunomodulatory and mild antiviral activity provides a plausible mechanistic basis for airway anti-inflammatory effects. One double-blind placebo-controlled RCT exists, but it evaluated acute bronchiolitis in children, not bronchitis broadly, and definitional mismatch with the target indication should be resolved before further evaluation.

Diabetic retinopathy / severe NPDR / diabetic cataract: These three predictions rest solely on zinc’s role as a cofactor for antioxidant enzymes in ocular tissue (Cu/Zn-SOD, metallothionein), a theoretical extrapolation with no direct clinical or preclinical zinc-sulfate studies identified. The two literature hits retrieved for diabetic retinopathy concern a vanadium compound and a PAI-1 transgenic mouse model respectively — neither studies zinc sulfate directly, and neither should be treated as supporting evidence.

Clinical Trial Evidence

Currently no related clinical trials registered for any of the five predicted indications (clinical_trials and ictrp_trials are empty across all entries).

Literature Evidence

Dermatitis (L2 — strongest evidence)

PMID	Year	Type	Journal	Key Findings
28168533	2017	RCT	Biol Trace Elem Res	Zinc sulfate ± growth hormone reduced radiation-induced skin injury in a placebo-controlled rat model
1090826	1975	Clinical study	NEJM	Oral zinc sulfate resolved acrodermatitis enteropathica in an adult patient with confirmed zinc deficiency
12383101	2002	Case report	Pediatr Dermatol	Zinc sulfate 40 mg/day resolved acrodermatitis enteropathica in a 21-month-old with low plasma zinc
16960696	2007	Case series	Eur J Pediatr	Zinc-deficiency dermatitis in 10 breast-fed preterm infants, often misdiagnosed as eczema/impetigo
6886096	1983	Case series/review	J Am Acad Dermatol	Acrodermatitis enteropathica case in pregnancy; markedly decreased zinc levels
30038513	2018	Open-label study	Clin Cosmet Investig Dermatol	Dermo-cosmetic product containing zinc sulfate improved hand eczema over 21 days
37308289	2023	RCT (veterinary — species mismatch)	Vet Rec	Zinc sulfate footbath vs. topical oxytetracycline for ovine digital dermatitis (not applicable to humans)
38670340	2024	Study (veterinary — species mismatch)	J Dairy Sci	Zinc sulfate footbath for digital dermatitis in dairy cattle (not applicable to humans)

Caution: Several additional hits (acrodermatitis enteropathica reviews/case reports, e.g. PMID 18328205, 37214014, 1990299, 2621529) reinforce the deficiency-correction indication but do not represent novel repurposing evidence. Veterinary studies (cattle/sheep) should be excluded from human indication assessment.

Bronchitis (L3)

PMID	Year	Type	Journal	Key Findings
28011970	2016	RCT (double-blind, placebo-controlled)	Infez Med	Oral zinc sulfate in 100 children with acute bronchiolitis (not bronchitis) showed effects on symptom recovery timeline
2063340	1991	Clinical-experimental study	Ter Arkh	Trace element (zinc/copper) correction studied in chronic obstructive bronchitis, rat and human data
6966823	1980	Occupational cohort study	Scand J Work Environ Health	Occupational zinc/cobalt exposure study; cobalt (not zinc) associated with increased asthma risk
33347551	2020	Animal study (poultry)	Avian Dis	Zinc/manganese feed additives tested against infectious bronchitis coronavirus in chickens (not human-applicable)
10774827	2000	Animal model	Toxicol Sci	Rat bronchitis model used to study particulate matter exposure, not zinc treatment

Diabetic Retinopathy (L5 — non-specific)

PMID	Year	Type	Journal	Key Findings
12203906	2002	Review/mechanistic	Chem Rec	Discusses vanadium (not zinc) complexes for diabetes management, mentions retinopathy as a complication
10892876	2000	Basic research (animal model)	Invest Ophthalmol Vis Sci	PAI-1 overexpression study in transgenic mice; not a zinc study

Neither publication studies zinc sulfate directly; both were retrieved on disease-term relevance only.

Severe Nonproliferative Diabetic Retinopathy / Diabetic Cataract (L5)

Currently no related literature available for either indication.

US Market Information

Zinc sulfate (unspecified form) is not currently marketed in Taiwan under this evidence pack (market_status: 未上市, total_licenses: 0). No NDA/license records are available for review.

Safety Considerations

Two data gaps are flagged for this candidate, one of which is Blocking:

TFDA label warnings/contraindications (Blocking gap, DG001): Not yet retrieved — this is required before any Stage 1 (S1) safety screening can proceed.
Mechanism of action (High-severity gap, DG002): Not yet retrieved from DrugBank.
Drug-drug interaction query returned no results (query_status: not_found, 0 interactions found) — this should be treated as “not yet searched,” not as “no interactions exist.”

Please refer to the official package insert (once available) for complete safety information.

Conclusion and Next Steps

Decision by indication:

Indication	Decision
Dermatitis (zinc-deficiency / radiation-induced subtypes)	Proceed with Guardrails
Bronchitis	Hold — Research Question (definitional mismatch: existing RCT is in bronchiolitis, not bronchitis)
Severe NPDR, Diabetic retinopathy, Diabetic cataract	Hold (L5, mechanism-only, no zinc-specific evidence)

Rationale: Dermatitis is the only indication with RCT-level evidence (radiation-induced dermatitis prevention) plus well-established deficiency-correction precedent (acrodermatitis enteropathica), justifying guarded progression. However, this is arguably not true “repurposing” but restoration-of-normal-physiology in a deficiency state, and should be scoped narrowly (zinc-deficiency and radiation-induced dermatitis subtypes) rather than general dermatitis. Bronchitis has only indirect/mismatched pediatric bronchiolitis data. The three ophthalmic/diabetic-complication predictions have no zinc-sulfate-specific evidence and rest entirely on theoretical antioxidant-cofactor reasoning.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA/FDA label warnings and contraindications before any indication can clear S1 safety screening.
Resolve DG002: obtain confirmed MOA from DrugBank to validate mechanistic rationale.
For dermatitis: narrow scope to zinc-deficiency and radiation-induced subtypes; exclude veterinary studies from the evidence base; seek human RCTs in general/atopic/contact dermatitis if broader indication is intended.
For bronchitis: clarify whether bronchiolitis evidence can be extrapolated to bronchitis, or seek trials specific to bronchitis.
For the three L5 ocular/diabetic-complication predictions: no further action recommended until direct zinc-sulfate preclinical or clinical data emerges.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.